Skip to main content

Advertisement

Log in

Validation of the Italian version of the PSP Quality of Life questionnaire

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Background

Progressive supranuclear palsy (PSP) is a rare rapidly progressive, neurodegenerative disease characterized by falls and ocular movement disturbances. The use of health-related quality of life (HR-QoL) measures allows assessing changes in health status induced by therapeutic interventions or disease progress in neurodegenerative diseases. The PSP-QoL is a 45-item, self-administered questionnaire designed to evaluate HR-QoL in PSP.

Methods and Results

Here, the PSP-QoL was translated into Italian and validated in 190 PSP (96 women and 94 men; mean age ± standard deviation, 72 ± 6.5; mean disease duration, 4.2 ± 2.3) patients diagnosed according to the Movement Disorder Society criteria and recruited in 16 third level movement disorders centers participating in the Neurecanet project. The mean PSP-QoL total score was 77.8 ± 37 (physical subscore, 46.5 ± 18.7; mental subscore, 33.6 ± 19.2). The internal consistency was high (Cronbach’s alpha = 0.954); corrected item-total correlation was > 0.40 for the majority of items. The significant and moderate correlation of the PSP-QoL with other HR-QoL measures as well as with motor and disability assessments indicated adequate convergent validity of the scale. Gender and geographic location presented a significant impact on the PSP-QoL in our sample with women and patients from the South of Italy scoring higher than their counterparts.

Conclusion

In conclusion, the Italian version of the PSP-QoL is an easy, reliable and valid tool for assessment of HR-QoL in PSP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

EQ-5D:

The EuroQoL questionnaire

EQ-VAS:

The EuroQoL Visual Analogue Scale

HADS:

The Hospital Anxiety and Depression Scale

HR-QoL:

Health-related Quality of Life

MDS:

Movement Disorder Society

MoCA:

Montreal Cognitive Assessment

PSP:

Progressive supranuclear palsy

PSP-QoL:

Progressive Supranuclear Palsy Quality of Life Questionnaire

PSP-RS:

Progressive Supranuclear Palsy Rating Scale

S&E:

The Schwab and England Scale

VAS:

Visual Analogue Scale

References

  1. Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16(7):552–563

    Article  Google Scholar 

  2. Golbe LI, Ohman-Strickland PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130(Pt 6):1552–1565

    Article  Google Scholar 

  3. Rubenstein LM, DeLeo A, Chrischilles EA (2001) Economic and health related quality of life considerations of new therapies in Parkinson’s disease. Pharmacoeconomics 19:729–752

    Article  CAS  Google Scholar 

  4. Spilker B (1996) Introduction. In: Spilker B (ed) Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Lippincot-Raven Publishers, Philadelphia, pp 1–10

    Google Scholar 

  5. Schrag A, Selai C, Quinn N, Lees A, Litvan I, Lang A, Poon Y, Bower J, Burn D, Hobart J (2006) Measuring quality of life in PSP. PSP-QoL Neurol 67:39–44

    CAS  Google Scholar 

  6. Acquadro C, Joyce CRB, Patrick DL, Ware JE, Wu AW, Scientific Advisory Committee (2004) Linguistic validation manual for patient reported outcomes (PRO) instruments. MAPI Research Trust, Lyon

  7. Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Müller U, Nilsson C, JWhitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I (2017) Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord 32(6):853–864

    Article  Google Scholar 

  8. The EuroQoL Group (1990) EuroQoL–a new facility for the measurement of health-related quality of life. Health Policy 16:199–208

    Article  Google Scholar 

  9. Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370

    Article  CAS  Google Scholar 

  10. Cronbach LJ (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16:297–334

    Article  Google Scholar 

  11. Scientific Advisory Committee of the Medical Outcomes Trust (2002) Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 11:193–205

    Article  Google Scholar 

  12. Nunnally JC, Bernstein IH (1994) Psychometric theory. McGraw-Hill, New York

    Google Scholar 

  13. Picillo M, Nicoletti A, Fetoni V, Garavaglia B, Barone P, Pellecchia MT (2017) The relevance of gender in Parkinson’s disease: a review. J Neurol 264(8):1583–1607

    Article  Google Scholar 

  14. Picillo M, Cuoco S, Amboni M, Bonifacio FP, Bruno A, Bruschi F, Cappiello A, De Micco R, De Rosa A, Di Biasio F, Elifani F, Erro R, Fabbri M, Falla M, Franco G, Frosini D, Galantucci S, Lazzeri G, Magistrelli L, Malaguti MC, Milner AV, Minafra B, Olivola E, Pilotto A, Rascunà C, Rizzetti MC, Schirinzi T, Borroni B, Ceravolo R, Di Fonzo A, Lopiano L, Marchese R, Mercuri NB, Modugno N, Nicoletti A, Padovani A, Santangelo G, Stefani A, Tessitore A, Volontè MA, Zangaglia R, Zappia M, Barone P. (2019) Validation of the Italian version of carers’ quality-of-life questionnaire for parkinsonism (PQoL Carer) in progressive supranuclear palsy. doi: https://doi.org/10.1007/s10072-019-03944-x

    Article  Google Scholar 

  15. Picillo M, Erro R, Cuoco S, Tepedino MF, Manara R, Pellecchia MT, Barone P, PSP Salerno Study Group (2018) MDS PSP criteria in real-life clinical setting: motor and cognitive characterization of subtypes. Mov Disord 33(8):1361–1365

    Article  Google Scholar 

Download references

Acknowledgments

Neurecanet project is an Italian Movement Disorders Network including 16 third level movement disorders centers coordinated by the CEMAND, University of Salerno (https://www.neurecanet.net), and supported by TEVA and Zambon.

We are grateful to the patients who participated in the study and to Susan Ainscough for the back translation of the PSP-QoL.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paolo Barone.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The project was approved by the local Ethics committee.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 501 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Picillo, M., Cuoco, S., Amboni, M. et al. Validation of the Italian version of the PSP Quality of Life questionnaire. Neurol Sci 40, 2587–2594 (2019). https://doi.org/10.1007/s10072-019-04010-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-019-04010-2

Keywords

Navigation